ARTHQ (Arch Therapeutics) Net Margin %: -18,241.94% (As of Jun. 2024)


ARTHQ Arch Therapeutics Inc ARTHQ
12 GF Score
Price $0.00
View Full Analysis

What is Arch Therapeutics Net Margin %?

Arch Therapeutics ARTHQ -99.00% 12 Net Margin % is -18,241.94% as of Jun. 2024. GuruFocus rates ARTHQ with a GF Score™ of 12/100.

Net margin is calculated as Net Income divided by its Revenue. Arch Therapeutics's Net Income for the three months ended in Jun. 2024 was $-5.66 Mil. Arch Therapeutics's Revenue for the three months ended in Jun. 2024 was $0.03 Mil. Therefore, Arch Therapeutics's net margin for the quarter that ended in Jun. 2024 was -18,241.94%.

The historical rank and industry rank for Arch Therapeutics's Net Margin % or its related term are showing as below:


ARTHQ's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.56
* Ranked among companies with meaningful Net Margin % only.

Arch Therapeutics  (OTCPK:ARTHQ) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Arch Therapeutics Net Margin % Related Terms

Arch Therapeutics Net Margin % Historical Data

* Premium members only.

The historical data trend for Arch Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arch Therapeutics Net Margin % Chart

Arch Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -52,000.00 -32,975.00 -9,188.16

Arch Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14,023.08 -6,142.50 -5,830.43 -4,590.63 -18,241.94

ARTHQ vs GRTSQ, MTEM, PXMD: Net Margin % Comparison

For the Biotechnology subindustry, Arch Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arch Therapeutics Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arch Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Arch Therapeutics's Net Margin % falls into.


ARTHQ
12GF Score
Arch Therapeutics Inc ARTHQ
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arch Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Arch Therapeutics's Net Margin for the fiscal year that ended in Sep. 2023 is calculated as

Net Margin=Net Income (A: Sep. 2023 )/Revenue (A: Sep. 2023 )
=-6.983/0.076
=-9,188.16 %

Arch Therapeutics's Net Margin for the quarter that ended in Jun. 2024 is calculated as

Net Margin=Net Income (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=-5.655/0.031
=-18,241.94 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -18,241.94% mean?
Arch Therapeutics (ARTHQ) has a Net Margin % of -18,241.94% as of Jun. 2024. Net margin is the ratio of total net income to net sales. View historical data on Arch Therapeutics and its competitors.
Is Arch Therapeutics' Net Margin % too high?
Arch Therapeutics' current Net Margin % is -18,241.94%. Overall, Arch Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Arch Therapeutics' Net Margin % compare to GRTSQ and MTEM?
Arch Therapeutics' Net Margin % of -18,241.94% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Arch Therapeutics and its competitors. Arch Therapeutics's current Net Margin % is -18,241.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arch Therapeutics stock overvalued right now?
Arch Therapeutics (ARTHQ) has a current Net Margin % of -18,241.94%. The current Net Margin % is -18,241.94%. Arch Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Arch Therapeutics (ARTHQ), the current Net Margin % is -18,241.94% as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Arch Therapeutics Business Description

Address 235 Walnut Street, Suite 6, Framingham, MA, USA, 01702
Arch Therapeutics Inc is a development-stage biotechnology company. It focuses on developing products that manage surgery and interventional care faster and safer by using a novel approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The company's primary product candidate, collectively known as the AC5 Devices (AC5), is designed to achieve hemostasis in surgical procedures. The company operates its business operations in the United States.
12GF Score

Get the complete analysis for ARTHQ

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price